Olcegepant

ArtNr	HY-10095-2mg
Hersteller	MedChem Express
CAS-Nr.	204697-65-4
Menge	2 mg
Quantity options	10mM/1mL 10 mg 25 mg 2 mg 50 mg 5 mg
Kategorie	Oncology Neuroscience Neural Lineage Markers Targets for Rodent Neurosciences Aging & Neurological Disorders Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Thyroid Cancer Neuronal Cell Markers
Typ	Inhibitors
Specific against	other
Purity	99.83
Formula	C38H47Br2N9O5
Citations	Adv Sci (Weinh). 2024 Jun 14:e2400242. Adv Sci (Weinh). 2025 Feb 17:e2409251. Biomed Res Int. 2022 Jun 16;2022:1585840. Br J Pharmacol. 2024 May 7. Cell Mol Life Sci. 2024 Aug 28;81(1):373. Cell Physiol Biochem. 2017;41(4):1457-1467. Cell Rep. 2024 Oct 15;43(10):114859. Cell. 2024 Jun 6;187(12):2935-2951.e19. Cephalalgia. 2024 Jul;44(7):3331024241254088. Department of Biology, Chemistry, Pharmacy. 2020 Oct. Freie Universitt Berlin. 2021 Feb. Front Cell Neurosci. 2018 Sep 11;12:304. Int Endod J. 2023 Oct 24. Int Immunopharmacol. 2024 Mar 6:130:111766. Int J Mol Sci. 2019 Nov 20;20(23):5826. J Headache Pain. 2022 Sep 30;23(1):128. J Headache Pain. 2024 Aug 21;25(1):136. J Headache Pain. 2024 Oct 10;25(1):176. J Invest Dermatol. 2019 Mar;139(3):656-664. Korean J Pain. 2022 Apr 1;35(2):173-182. Nat Med. 2016 Oct;22(10):1160-1169. Neuropeptides. 2015 Aug;52:31-7. Orthop J Sports Med. July 13, 2021. Peptides. 2021 Jan;135:170423. Research Square Print. August 19th, 2022. Sci Rep. 2020 Jul 10;10(1):11408. Sci Rep. 2022 Aug 16;12(1):13894. Small Methods. 2024 Aug 1:e2400216. Vascul Pharmacol. 2017 Mar;90:36-43. Adv Sci (Weinh). 2021 Oct 28;e2103005. Cephalalgia. 2020 Aug;40(9):924-934. Cephalalgia. 2021 Mar;41(3):329-339. Cephalalgia. 2019 Dec;39(14):1827-1837. J Headache Pain. 2022 Mar 8;23(1):35. Journal of Traditional Chinese Medical Sciences. 21 June 2022. Sci Rep. 2018 Jan 30;8(1):1836. [1]Rudolf K, et al. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine. J Med Chem. 2005 Sep 22;48(19):5921-31. [2]Doods H, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000 Feb;129(3):420-3. [3]Edvinsson L, et al. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omentalarteries and in SK-N-MC cells. Eur J Pharmacol. 2002 Jan 2;434(1-2):49-53. [4]Sixt ML, et al. Calcitonin gene-related peptide receptor antagonist Olcegepant acts in the spinal trigeminal nucleus. Brain. 2009 Nov;132(Pt 11):3134-41. [5]Michot B, et al. Differential effects of calcitonin gene-related peptide receptor blockade by Olcegepant on mechanical allodynia induced by ligation of the infraorbital nerve vs the sciatic nerve in the rat. Pain. 2012 Sep;153(9):1939-48.
Smiles	O=C1N(CC2=C(N1)C=CC=C2)C3CCN(C(N[C@@H](C(N[C@H](C(N4CCN(C5=CC=NC=C5)CC4)=O)CCCCN)=O)CC6=CC(Br)=C(C(Br)=C6)O)=O)CC3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BIBN-4096; BIBN 4096BS
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	CGRP Receptor
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	869.65
Product Description	Olcegepant (BIBN-4096) is a potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor with IC50 of 0.03 nM and Ki of 14.4 pM for human CGRP[1][2].
Manufacturer - Research Area	Neurological Disease
Solubility	DMSO : ≥ 50 mg/mL
Manufacturer - Pathway	GPCR/G Protein; Neuronal Signaling
Clinical information	Phase 2

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-10095-2mg-safety-datasheet.pdf